evoke and evoke+: Design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimers disease
The glucagon arm appears to contribute substantively to body-composition outcomes (favouring fat-mass reduction) without offsetting the glycemic outcomes of the GLP-1/GIP arms (PMID 39515565, PMID 40609566)
Authors contributions Designed and conducted the study, performed data acquisition and analysis, and wrote the manuscript: Zhang W, Xue J Collected and managed data: Wang J, Ni D, Zhou W Performed data management: Wang B, Shi J Conceived and designed the study, conducted it, interpreted the data, and revised the manuscript: Wang A All the authors have read and approved the final version of this manuscript
Examples include: Loratadine + pseudoephedrine (Claritin-D) Cetirizine + pseudoephedrine (Zyrtec-D) Since people with allergic rhinitis often take one or more of these medications daily, it is important to know if they interact with semaglutide
Accelerated fat loss Two mechanisms working together to help you shed fat faster than diet and exercise alone